[Blood coagulation and fibrinolysis in women receiving estrogen, gestagen and estrogen-gestagen-contraceptives (author's transl)].
Eight femal subjects received a contraceptive with a low estrogen content (Neogynon), the estrogen component (50 mug ethinylestradiol) and consecutively the gestagen component (250 mug D-Norgestrel) of the contraceptive. Each treatment cycle was followed by a control cycle. At various times of the control and therapy cycles several coagulation and fibrinolytic parameters were investigated. Statistical analyses were performed by multivariate two-factorial analysis of variance. Plasminogen exhibities a statistically significant increase during the treatment with ethinylestradiol and the combination of this steroid with D-norgestrel. No significant changes were found for all other parameters, including partial thromboplastin time, fibriogen, factors X, IX, VIII, factor VIII-related antigen, antithrombin III and fibrin(ogen)degradation products.
D000328:Adult; D000991:Antithrombins; D001777:Blood Coagulation / Q000187:drug effects*; D003276:Contraceptives, Oral / Q000009:adverse effects; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000494:pharmacology*; D005164:Factor IX; D005169:Factor VIII; D005170:Factor X; D005260:Female; D005340:Fibrinogen; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D009644:Norgestrel / Q000494:pharmacology*; D010958:Plasminogen
D000991:Antithrombins; D003276:Contraceptives, Oral; D004338:Drug Combinations; D009644:Norgestrel; D004997:Ethinyl Estradiol; D005169:Factor VIII; D005164:Factor IX; D005170:Factor X; D005340:Fibrinogen; D010958:Plasminogen; D007986:Luteinizing Hormone
Beeinflussung von Blutgerinnung und Fibrinolyse durch Oestrogen, Gestagen und eine Oestrogen-Gestagen-Kombination